A pan-cancer blueprint of genomics alterations and transcriptional regulation of Siglecs, and implications in prognosis and immunotherapy responsiveness

Affiliations

• ¹ Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, MOE Key Laboratory of Major Diseases in Children; Rare Disease Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
• ² Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
• ³ Beijing ClouDNA Technology Co., Ltd., Beijing, China.
• ⁴ Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
• ⁵ Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.